focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Hi Shiraz,
I for one took as a positive and am in here for the LT. The good DR answered many of the questions and put my mind at more ease. I don’t need Nasdaq to tell me if it’s positive. Lots to come in the company, in 2020 and 2021.
Should they decide to keep Accustem and not sell, it’s a viable way to extract maximum value. Yes cash will need to be generated, IPO or placing. That’s normal with any new company.
Should demerger and choose to sell, that’s fine for me too. Either way LT Accustem will be a welcome addition to the PF whichever way it chooses to go.
My eyes are on Foralumab trials and all it has to offer, and the many it can benefit.
For me, the sooner the demerger is over the better, so we can focus on Tiziana. GLA
Well said! Hours of negativity and squabbling on this board after such a positive call last night :(
Well said BMO3
14th October 1st Hearing Re Demerger
http://announcements.telegraph.co.uk/other/244996/cr-2020-003627
My view and take re de-merger is that on the 30th we get attributed accustem shares, however as no value had been placed we may not see too much of a drop. Also bare in mind the RNS stated accustem was only valued at 4m ( which I assume is dev cost) to the company.
Seeing as it won’t be listed for 2 months (December probably) that gives TILS two months to find its value less Accustem. And 2 months to get news out re Foralumab, Brazil news, main market move and FDA approval.
All IMO GLA
Apologies, meant 1st hearing.
Ruling is today. So most likely end of day
Whimax, agreed on the buy out.
Any positive news/data coming out of Brazil will confirm to large Pharma to initiate a buy-out.
Now would be a great time to release a red chip report highlighting the fully human MAB developed, mentioning the Brazil trials and the MAB related patents / tech that Tiziana has
Good article,
https://www.bloomberg.com/news/articles/2020-10-11/covid-19-inhaled-vaccines-may-be-more-effective-than-injections
If only there was a company that had developed a technology delivering treatment straight to the source
https://www.bloomberg.com/news/articles/2020-10-11/covid-19-inhaled-vaccines-may-be-more-effective-than-injections
Raaydaar got to agree with you.
Shares being credited in customers account on the 30th but we as yet have no idea the date accustom will be officially listed? On what exchange or the initial IPO price? For that reason there may not be a large initial sell off as we just don’t know the real value.
That being said, with trials starting shortly, direction of MAB accustem
De-merger will be over shadowed by the Crown Jewels as the Dr said
Most Covid stocks up today apart from us, being held down for whatever reason. Big order? Short? Awaiting its master the Nasdaq?
But as they say nothing goes up in a straight line. Predict it finishes flat today. GLA, best is yet to come
Nice read on MAB’s
TILS should lead the way in administration with their inhalation tech and patents
https://www.washingtonpost.com/health/2020/09/30/monoclonal-antibodies-to-treat-covid-19/
Yep, from RNS regarding Brazil Trials
“ collaborative clinical study investigating nasally administered Foralumab in COVID-19 patients in Brazil, either alone or in combination with orally administered dexamethasone”
“ Thus, we believe the clinical strategy with nasal administration of Foralumab either alone or in combination with dexamethasone to treat COVID-19 patients is highly innovative and scientifically very sound.”
Is there a way to know who is shorting? At that % level of shorting it’s got to be a number of institutions / funds
I know in the U.K. shorttracker.co.uk shows who is at it for each stock
Y-Alam, saw that post and could see the merit in it.
If they spent $2.8 billion buy Oncotype-DX, are they going to let Tiziana with a few £100 million mkt cap disrupt their hugely profitable market. As said, it’s just a theory and my opinion.
Good luck all. Let’s see how the week closes out.
Throwing it out there. As anything is possible these days. Could exact sciences be behind this.......
Good luck all. It’s a tough hold, but one I will be holding onto till the demerger.
Not sure if already posted,Monoclonal Antibody market predicted to be $350 billion by 2027
https://www.globenewswire.com/news-release/2020/09/14/2092946/0/en/Monoclonal-Antibody-Therapy-Market-to-Reach-USD-350-10-Billion-by-2027-Increasing-Number-of-Regulatory-Approvals-Will-Aid-Growth-says-Fortune-Business-Insights.html
BMO3 good point. Don’t forget to couple great parent RNS’s as well.
Last 6-7 weeks we have had lots of great news and yet we are below placing. Can’t get my head around it